JP2022534813A5 - - Google Patents
Info
- Publication number
- JP2022534813A5 JP2022534813A5 JP2022515977A JP2022515977A JP2022534813A5 JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5 JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell population
- grna
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852238P | 2019-05-23 | 2019-05-23 | |
| US62/852,238 | 2019-05-23 | ||
| US202062962127P | 2020-01-16 | 2020-01-16 | |
| US62/962,127 | 2020-01-16 | ||
| PCT/US2020/034391 WO2020237217A1 (en) | 2019-05-23 | 2020-05-22 | Compositions and methods for cd33 modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534813A JP2022534813A (ja) | 2022-08-03 |
| JP2022534813A5 true JP2022534813A5 (enExample) | 2023-05-24 |
Family
ID=71078652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515977A Pending JP2022534813A (ja) | 2019-05-23 | 2020-05-22 | Ｃｄ３３改変のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220228153A1 (enExample) |
| EP (1) | EP3973057A1 (enExample) |
| JP (1) | JP2022534813A (enExample) |
| KR (1) | KR20220035877A (enExample) |
| CN (1) | CN114423865A (enExample) |
| AU (1) | AU2020280103A1 (enExample) |
| CA (1) | CA3141732A1 (enExample) |
| MX (1) | MX2021014306A (enExample) |
| WO (1) | WO2020237217A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2022125633A1 (en) * | 2020-12-08 | 2022-06-16 | The Regents Of The University Of California | Crispr ribonucleoprotein complex genome editing of human innate immune cells |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2969619A1 (en) * | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| WO2017053729A1 (en) * | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CA3048434A1 (en) | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| BR112021008041A2 (pt) * | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com células imunitárias anti-cd33 |
| BR112021014010A2 (pt) * | 2019-01-16 | 2021-09-21 | The Trustees Of Columbia University In The City Of New York | Composições e métodos para inibição de antígenos linhagem-específicos |
-
2020
- 2020-05-22 AU AU2020280103A patent/AU2020280103A1/en not_active Abandoned
- 2020-05-22 WO PCT/US2020/034391 patent/WO2020237217A1/en not_active Ceased
- 2020-05-22 EP EP20732076.3A patent/EP3973057A1/en not_active Withdrawn
- 2020-05-22 CN CN202080050633.7A patent/CN114423865A/zh active Pending
- 2020-05-22 CA CA3141732A patent/CA3141732A1/en active Pending
- 2020-05-22 KR KR1020217041969A patent/KR20220035877A/ko not_active Withdrawn
- 2020-05-22 US US17/613,387 patent/US20220228153A1/en active Pending
- 2020-05-22 JP JP2022515977A patent/JP2022534813A/ja active Pending
- 2020-05-22 MX MX2021014306A patent/MX2021014306A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534813A5 (enExample) | ||
| US11639523B2 (en) | Type V CRISPR-Cas systems and use thereof | |
| JP7094323B2 (ja) | 最適化機能ＣＲＩＳＰＲ－Ｃａｓ系による配列操作のための系、方法および組成物 | |
| TWI906782B (zh) | 新型crispr酶以及系統 | |
| US10190137B2 (en) | CRISPR-related methods and compositions with governing gRNAS | |
| AU2015342749B2 (en) | Methods for improving CRISPR/Cas-mediated genome-editing | |
| Zhao et al. | Review of applications of CRISPR-Cas9 gene-editing technology in cancer research | |
| WO2022140577A2 (en) | Compositions and methods for epigenetic editing | |
| JP2022107776A5 (enExample) | ||
| JP2023541457A5 (enExample) | ||
| Amoasii et al. | In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse | |
| US20250304934A1 (en) | Reprogrammable fanzor polynucleotides and uses thereof | |
| JP2022538084A5 (enExample) | ||
| Guzzo et al. | A CRISPR interference system for efficient and rapid gene knockdown in Caulobacter crescentus | |
| Jin et al. | Engineered lipid nanoparticles for the treatment of pulmonary fibrosis by regulating epithelial‐mesenchymal transition in the lungs | |
| Chen et al. | In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA | |
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| Yang et al. | CRISPR Cas9 in pancreatic cancer research | |
| JP2024534387A5 (enExample) | ||
| Mukushkina et al. | In silico prediction of miRNA interactions with candidate atherosclerosis gene mRNAs | |
| JP2022526297A5 (enExample) | ||
| JP2023541458A5 (enExample) | ||
| JP2022526099A5 (enExample) | ||
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| Zhou et al. | Development of a conditional plasmid for gene deletion in non-model Fusobacterium nucleatum strains |